Abstract:Background: MicroRNA-22 (miR-22) has recently been reported to play a regulatory role during vascular smooth muscle cell (VSMC) differentiation from stem cells, but little is known about its target genes and related pathways in mature VSMC phenotypic modulation or its clinical implication in neointima formation following vascular injury. Methods: We applied a wire-injury mouse model, and local delivery of AgomiR-22 or miR-22 inhibitor, as well, to explore the therapeutic potential of miR-22 in vascular diseases. Furthermore, normal and diseased human femoral arteries were harvested, and various in vivo, ex vivo, and in vitro models of VSMC phenotype switching were conducted to examine miR-22 expression during VSMC phenotype switching. Results: Expression of miR-22 was closely regulated during VSMC phenotypic modulation. miR-22 overexpression significantly increased expression of VSMC marker genes and inhibited VSMC proliferation and migration, whereas the opposite effect was observed when endogenous miR-22 was knocked down. As expected, 2 previously reported miR-22 target genes, MECP2 (methyl-CpG binding protein 2) and histone deacetylase 4, exhibited a regulatory role in VSMC phenotypic modulation. A transcriptional regulator and oncoprotein, EVI1 (ecotropic virus integration site 1 protein homolog), has been identified as a novel miR-22 target gene in VSMC phenotypic modulation. It is noteworthy that overexpression of miR-22 in the injured vessels significantly reduced the expression of its target genes, decreased VSMC proliferation, and inhibited neointima formation in wire-injured femoral arteries, whereas the opposite effect was observed with local application of a miR-22 inhibitor to injured arteries. We next examined the clinical relevance of miR-22 expression and its target genes in human femoral arteries. We found that miR-22 expression was significantly reduced, whereas MECP2 and EVI1 expression levels were dramatically increased, in diseased in comparison with healthy femoral human arteries. This inverse relationship between miR-22 and MECP2 and EVI1 was evident in both healthy and diseased human femoral arteries. Conclusions: Our data demonstrate that miR-22 and EVI1 are novel regulators of VSMC function, specifically during neointima hyperplasia, offering a novel therapeutic opportunity for treating vascular diseases.

The Role of SM22α in Vascular Smooth Muscle Cells

SMOC2 promoted vascular smooth muscle cell proliferation, migration, and extracellular matrix degradation by activating BMP/TGF-I31

Smooth muscle 22 alpha protein inhibits VSMC foam cell formation by supporting normal LXRα signaling, ameliorating atherosclerosis

Sm22 Alpha Suppresses Cytokine- Induced Inflammation And The Transcription Of Nf-Kappa B Inducing Kinase (Nik) By Modulating Srf Transcriptional Activity In Vascular Smooth Muscle Cells

Abstract 12723: Smooth Muscle-Derived CD34 + Cells after Vascular Injury Contribute to Vascular Remodeling

Discovery of an Evolutionarily Conserved Smooth Muscle Cell-Specific Lncrna CARMN

The Role of Src Homology 2 Containing Protein Tyrosine Phosphatase 2 in Vascular Smooth Muscle Cell Migration and Proliferation

Assessing serum levels of SM22α as a new biomarker for patients with aortic aneurysm/dissection

An overview of potential molecular mechanisms involved in VSMC phenotypic modulation

A Controversial Tumor Marker: is SM22 a Proper Biomarker for Gastric Cancer Cells?

SM22α Deletion Contributes to Neurocognitive Impairment in Mice through Modulating Vascular Smooth Muscle Cell Phenotypes

Abstract 009: Ribosomal Profiling of Vascular Smooth Muscle Cells in Vivo Identifies Cell-type Specific Transcripts and Enrichment of Blood Pressure Associated Genes

How vascular smooth muscle cell phenotype switching contributes to vascular disease

Mir-22 is a Novel Mediator of Vascular Smooth Muscle Cell Phenotypic Modulation and Neointima Formation

SMYD2 regulates vascular smooth muscle cell phenotypic switching and intimal hyperplasia via interaction with myocardin

Molecular Cloning and Expression of a Smooth Muscle-Specific Gene SM22α in Zebrafish

Origin And Differentiation Of Vascular Smooth Muscle Cells

Vascular Smooth Muscle Cells Phenotypic Switching in Cardiovascular Diseases

SWI/SNF Complex in Vascular Smooth Muscle Cells and Its Implications in Cardiovascular Pathologies

MicroRNA-145, a Novel Smooth Muscle Cell Phenotypic Marker and Modulator, Controls Vascular Neointimal Lesion Formation

Expression Differential and Biological Significance of SM22mRNA in Gastric Cancer and Normal Tissues